U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Uterine corpus epithelioid leiomyosarcoma

MedGen UID:
274363
•Concept ID:
C1519851
•
Neoplastic Process
Synonyms: body of uterus epithelioid leiomyosarcoma; epithelioid leiomyosarcoma of body of uterus; Uterine Corpus Epithelioid Leiomyosarcoma; uterine corpus epithelioid leiomyosarcoma; uterine epithelioid leiomyosarcoma
 
Monarch Initiative: MONDO:0003782

Definition

A morphologic variant of leiomyosarcoma arising from the uterine corpus. It is characterized by the presence of epithelioid round cells with eosinophilic to clear cytoplasm. [from NCI]

Professional guidelines

PubMed

Uterine Morcellation for Presumed Leiomyomas: ACOG Committee Opinion, Number 822.
Obstet Gynecol 2021 Mar 1;137(3):e63-e74. doi: 10.1097/AOG.0000000000004291. PMID: 33595252
ACOG Committee Opinion No. 770: Uterine Morcellation for Presumed Leiomyomas.
Obstet Gynecol 2019 Mar;133(3):e238-e248. doi: 10.1097/AOG.0000000000003126. PMID: 30801477
Treatment, results and prognostic factors in stage I and II sarcomas of the corpus uteri.
Vongtama V, Karlen JR, Piver SM, Tsukada Y, Moore RH
AJR Am J Roentgenol 1976 Jan;126(1):139-47. doi: 10.2214/ajr.126.1.139. PMID: 175673

Recent clinical studies

Etiology

Recent Developments in Surgical Pathology of the Uterine Corpus.
Hanley KZ, Birdsong GG, Mosunjac MB
Arch Pathol Lab Med 2017 Apr;141(4):528-541. Epub 2017 Feb 28 doi: 10.5858/arpa.2016-0284-SA. PMID: 28353387
Major clinical research advances in gynecologic cancer in 2015.
Suh DH, Kim M, Kim HJ, Lee KH, Kim JW
J Gynecol Oncol 2016 Nov;27(6):e53. doi: 10.3802/jgo.2016.27.e53. PMID: 27775259Free PMC Article
Malignant tumors of the uterine corpus: molecular background of their origin.
Brany D, Dvorska D, Nachajova M, Slavik P, Burjanivova T
Tumour Biol 2015 Sep;36(9):6615-21. Epub 2015 Aug 26 doi: 10.1007/s13277-015-3824-1. PMID: 26307392
Major clinical research advances in gynecologic cancer in 2014.
Suh DH, Lee KH, Kim K, Kang S, Kim JW
J Gynecol Oncol 2015 Apr;26(2):156-67. doi: 10.3802/jgo.2015.26.2.156. PMID: 25872896Free PMC Article
Heterologous and rare homologous sarcomas of the uterine corpus: a clinicopathologic review.
Fadare O
Adv Anat Pathol 2011 Jan;18(1):60-74. doi: 10.1097/PAP.0b013e3182026be7. PMID: 21169739

Diagnosis

Expanding the Spectrum of NR4A3 Fusion-Positive Gynecologic Leiomyosarcomas.
Momeni-Boroujeni A, Mullaney K, DiNapoli SE, Leitao MM Jr, Hensley ML, Katabi N, Allison DHR, Park KJ, Antonescu CR, Chiang S
Mod Pathol 2024 May;37(5):100474. Epub 2024 Mar 18 doi: 10.1016/j.modpat.2024.100474. PMID: 38508521
Recent Developments in Surgical Pathology of the Uterine Corpus.
Hanley KZ, Birdsong GG, Mosunjac MB
Arch Pathol Lab Med 2017 Apr;141(4):528-541. Epub 2017 Feb 28 doi: 10.5858/arpa.2016-0284-SA. PMID: 28353387
Major clinical research advances in gynecologic cancer in 2014.
Suh DH, Lee KH, Kim K, Kang S, Kim JW
J Gynecol Oncol 2015 Apr;26(2):156-67. doi: 10.3802/jgo.2015.26.2.156. PMID: 25872896Free PMC Article
Uterine leiomyosarcoma: a review article.
Gockley AA, Rauh-Hain JA, del Carmen MG
Int J Gynecol Cancer 2014 Nov;24(9):1538-42. doi: 10.1097/IGC.0000000000000290. PMID: 25304676
Heterologous and rare homologous sarcomas of the uterine corpus: a clinicopathologic review.
Fadare O
Adv Anat Pathol 2011 Jan;18(1):60-74. doi: 10.1097/PAP.0b013e3182026be7. PMID: 21169739

Therapy

Long-term risk of uterine malignancies in women with uterine fibroids confirmed by myomectomy: a population-based study.
Yuk JS, Kim M
J Obstet Gynaecol 2022 Oct;42(7):3067-3072. Epub 2022 Jul 1 doi: 10.1080/01443615.2022.2091925. PMID: 35775461
Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052).
Asano H, Oda K, Yoshihara K, Ito YM, Matsumura N, Shimada M, Watari H, Enomoto T
J Gynecol Oncol 2022 Jul;33(4):e55. Epub 2022 May 3 doi: 10.3802/jgo.2022.33.e55. PMID: 35557035Free PMC Article
CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma.
Nakae R, Matsuzaki S, Serada S, Matsuo K, Shiomi M, Sato K, Nagase Y, Matsuzaki S, Nakagawa S, Hiramatsu K, Okazawa A, Kimura T, Egawa-Takata T, Kobayashi E, Ueda Y, Yoshino K, Naka T, Kimura T
Am J Obstet Gynecol 2021 Feb;224(2):197.e1-197.e23. Epub 2020 Aug 19 doi: 10.1016/j.ajog.2020.08.028. PMID: 32822640
Major clinical research advances in gynecologic cancer in 2015.
Suh DH, Kim M, Kim HJ, Lee KH, Kim JW
J Gynecol Oncol 2016 Nov;27(6):e53. doi: 10.3802/jgo.2016.27.e53. PMID: 27775259Free PMC Article
Major clinical research advances in gynecologic cancer in 2014.
Suh DH, Lee KH, Kim K, Kang S, Kim JW
J Gynecol Oncol 2015 Apr;26(2):156-67. doi: 10.3802/jgo.2015.26.2.156. PMID: 25872896Free PMC Article

Prognosis

Recent Developments in Surgical Pathology of the Uterine Corpus.
Hanley KZ, Birdsong GG, Mosunjac MB
Arch Pathol Lab Med 2017 Apr;141(4):528-541. Epub 2017 Feb 28 doi: 10.5858/arpa.2016-0284-SA. PMID: 28353387
Malignant tumors of the uterine corpus: molecular background of their origin.
Brany D, Dvorska D, Nachajova M, Slavik P, Burjanivova T
Tumour Biol 2015 Sep;36(9):6615-21. Epub 2015 Aug 26 doi: 10.1007/s13277-015-3824-1. PMID: 26307392
Uterine leiomyosarcoma: a review article.
Gockley AA, Rauh-Hain JA, del Carmen MG
Int J Gynecol Cancer 2014 Nov;24(9):1538-42. doi: 10.1097/IGC.0000000000000290. PMID: 25304676
Heterologous and rare homologous sarcomas of the uterine corpus: a clinicopathologic review.
Fadare O
Adv Anat Pathol 2011 Jan;18(1):60-74. doi: 10.1097/PAP.0b013e3182026be7. PMID: 21169739
Gynecological sarcomas.
DiSaia PJ, Pecorelli S
Semin Surg Oncol 1994 Sep-Oct;10(5):369-73. doi: 10.1002/ssu.2980100510. PMID: 7997731

Clinical prediction guides

Expanding the Spectrum of NR4A3 Fusion-Positive Gynecologic Leiomyosarcomas.
Momeni-Boroujeni A, Mullaney K, DiNapoli SE, Leitao MM Jr, Hensley ML, Katabi N, Allison DHR, Park KJ, Antonescu CR, Chiang S
Mod Pathol 2024 May;37(5):100474. Epub 2024 Mar 18 doi: 10.1016/j.modpat.2024.100474. PMID: 38508521
CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma.
Nakae R, Matsuzaki S, Serada S, Matsuo K, Shiomi M, Sato K, Nagase Y, Matsuzaki S, Nakagawa S, Hiramatsu K, Okazawa A, Kimura T, Egawa-Takata T, Kobayashi E, Ueda Y, Yoshino K, Naka T, Kimura T
Am J Obstet Gynecol 2021 Feb;224(2):197.e1-197.e23. Epub 2020 Aug 19 doi: 10.1016/j.ajog.2020.08.028. PMID: 32822640
Major clinical research advances in gynecologic cancer in 2015.
Suh DH, Kim M, Kim HJ, Lee KH, Kim JW
J Gynecol Oncol 2016 Nov;27(6):e53. doi: 10.3802/jgo.2016.27.e53. PMID: 27775259Free PMC Article
Major clinical research advances in gynecologic cancer in 2014.
Suh DH, Lee KH, Kim K, Kang S, Kim JW
J Gynecol Oncol 2015 Apr;26(2):156-67. doi: 10.3802/jgo.2015.26.2.156. PMID: 25872896Free PMC Article
Heterologous and rare homologous sarcomas of the uterine corpus: a clinicopathologic review.
Fadare O
Adv Anat Pathol 2011 Jan;18(1):60-74. doi: 10.1097/PAP.0b013e3182026be7. PMID: 21169739

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...